• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Orthofix Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

    4/7/25 4:48:02 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care
    Get the next $OFIX alert in real time by email
    8-K
    false000088462400008846242025-04-012025-04-01

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 01, 2025

     

     

    ORTHOFIX MEDICAL INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    000-19961

    98-1340767

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    3451 Plano Parkway

     

    Lewisville, Texas

     

    75056

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (214) 937-2000

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common stock, $0.10 par value per share

     

    OFIX

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 1.01 Entry into a Material Definitive Agreement.

    On April 1, 2025, Orthofix Medical Inc. (the “Company”) became tenant under a new lease governing its Carlsbad, California office location (5770 Armada Drive) (the “New Lease”), which became effective on such date. The Company had previously been tenant pursuant to a prior sublease with respect to such location (which is filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024), which sublease terminated as of such date.

    The New Lease provides for a term through October 31, 2037. The Company’s monthly rent, which includes 3.5% annual increases, is estimated to have a total pre-tax occupancy cost of approximately $34.6 million over the 12.5 year term of the lease. In addition to monthly rent, the Company is also obligated to pay the real estate taxes, insurance costs and utility and other expenses for the property.

    Item 1.02 Termination of a Material Definitive Agreement.

    The disclosure contained in Item 1.01 with respect to the termination of the Company’s prior lease is incorporated herein by reference.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Orthofix Medical Inc.

     

     

     

     

    Date:

    April 7, 2025

    By:

    /s/ J. Andrés Cedrón

     

     

     

    J. Andrés Cedrón
    Chief Legal Officer

     


    Get the next $OFIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OFIX

    DatePrice TargetRatingAnalyst
    1/22/2025$24.00Buy
    Canaccord Genuity
    11/8/2024$18.00 → $24.00Hold → Buy
    Stifel
    5/8/2024$15.00 → $20.00Neutral → Buy
    ROTH MKM
    10/20/2023$12.00Neutral
    ROTH MKM
    9/12/2023Buy → Neutral
    BTIG Research
    9/12/2023Buy → Hold
    Stifel
    7/19/2023$27.00Buy
    BTIG Research
    3/4/2022$41.00 → $45.00Hold → Buy
    Stifel
    More analyst ratings

    $OFIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Engine Capital Management, Lp bought $13,881 worth of shares (1,250 units at $11.11) (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    7/7/25 5:43:59 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Finegan Michael was granted 26,087 shares, increasing direct ownership by 83% to 57,391 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    6/23/25 4:19:38 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Paolucci Michael E was granted 18,841 shares, increasing direct ownership by 28% to 86,948 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    6/23/25 4:19:09 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    SEC Filings

    View All

    SEC Form 10-Q filed by Orthofix Medical Inc.

    10-Q - Orthofix Medical Inc. (0000884624) (Filer)

    8/5/25 7:05:06 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Orthofix Medical Inc. (0000884624) (Filer)

    8/5/25 7:03:36 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - Orthofix Medical Inc. (0000884624) (Filer)

    6/20/25 9:00:28 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orthofix Reports Second Quarter 2025 Financial Results

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2025, and reaffirmed its full-year 2025 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6® product lines. Highlights Second quarter 2025 net sales of $203.1 million, including sales from M6® artificial cervical and lumbar discs, and pro forma net sales of $200.7 million, excluding sales from M6® discs, representing an increase of 2% on a reported basis and 4% on a pro forma constant currency basis compared to second quarter 2024 U.S. Spine

    8/5/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference

    Wednesday, August 13, 2025 at 9:00 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate at the Canaccord Genuity 45th Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 13, 2025 at 9:00 am Eastern Time. Interested parties can access the live and archived webcast of the presentation in the "Events & Presentations" section of the Orthofix Investor Relations Website at ir.orthofix.com. Internet Posting of Information Orthofix routinely posts information that may be important to investors in the "Investors" section of its website at www.orthofix.com. Or

    7/16/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Report Second Quarter 2025 Financial Results

    Company to Host Conference Call on Tuesday, August 5, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 4830464. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Info

    7/15/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Orthofix with a new price target

    Canaccord Genuity initiated coverage of Orthofix with a rating of Buy and set a new price target of $24.00

    1/22/25 7:47:50 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix upgraded by Stifel with a new price target

    Stifel upgraded Orthofix from Hold to Buy and set a new price target of $24.00 from $18.00 previously

    11/8/24 8:23:19 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix upgraded by ROTH MKM with a new price target

    ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously

    5/8/24 6:31:28 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Engine Capital Management, Lp bought $13,881 worth of shares (1,250 units at $11.11) (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    7/7/25 5:43:59 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Director Bazaar Alan Lee bought $24,570 worth of shares (2,250 units at $10.92), increasing direct ownership by 8% to 30,983 units (SEC Form 4)

    4 - Orthofix Medical Inc. (0000884624) (Issuer)

    6/5/25 5:11:05 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Amendment: Large owner Engine Capital Management, Lp bought $1,231,000 worth of shares (100,000 units at $12.31) (SEC Form 4)

    4/A - Orthofix Medical Inc. (0000884624) (Issuer)

    5/14/25 4:34:50 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Orthofix Medical Inc.

    SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)

    11/14/24 5:20:27 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Orthofix Medical Inc.

    SC 13G - Orthofix Medical Inc. (0000884624) (Subject)

    11/13/24 5:03:21 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Orthofix Medical Inc. (Amendment)

    SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)

    4/22/24 5:00:33 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Financials

    Live finance-specific insights

    View All

    Orthofix Reports Second Quarter 2025 Financial Results

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2025, and reaffirmed its full-year 2025 financial guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6® product lines. Highlights Second quarter 2025 net sales of $203.1 million, including sales from M6® artificial cervical and lumbar discs, and pro forma net sales of $200.7 million, excluding sales from M6® discs, representing an increase of 2% on a reported basis and 4% on a pro forma constant currency basis compared to second quarter 2024 U.S. Spine

    8/5/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix to Report Second Quarter 2025 Financial Results

    Company to Host Conference Call on Tuesday, August 5, 2025 at 8:30 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referencing the conference ID 4830464. A webcast of the conference call and a copy of the release may be accessed at ir.Orthofix.com. Internet Posting of Info

    7/15/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Reports First Quarter 2025 Financial Results

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6-C™ and M6-L™ artificial disc product lines. Highlights First quarter 2025 net sales of $193.6 million, including sales from its M6 artificial cervical and lumbar discs, and pro forma net sales of $189.2 million, excluding sales from its M6 discs, representing an increa

    5/6/25 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    $OFIX
    Leadership Updates

    Live Leadership Updates

    View All

    Orthofix Announces Appointment of Vickie Capps to Board of Directors

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312538957/en/Vickie Capps (Photo: Business Wire) "Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix," said Michael Finegan, Chairman of Orthofix. "Her expertise in global business operations, strategic business development and corporate finance will provide the Board with a tremendously valuable perspective as we seek to deliver profitable growth and significa

    3/12/25 8:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b

    8/15/24 5:52:00 PM ET
    $OFIX
    Medical/Dental Instruments
    Health Care

    Orthofix Names Stephanie Walsh Chief Human Resources Officer

    Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H

    7/16/24 7:00:00 AM ET
    $OFIX
    Medical/Dental Instruments
    Health Care